Spinraza Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The spinraza market research report is one of a series of new reports that provides spinraza market statistics, including the spinraza industry's global market size, regional shares, competitors with a spinraza market share, detailed spinraza market segments, market trends and opportunities, and any further data you may need to thrive in the spinraza industry. This spinraza market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to increasing awareness of spinal muscular atrophy (SMA), rising healthcare expenditure in emerging markets, expanding reimbursement policies for SMA treatments, growing patient advocacy and support organizations, and increasing number of clinical studies. Major trends in the forecast period include development of combination therapies, advancements in drug delivery methods, advancements in gene therapy, innovations in diagnostic technologies, and adoption of AI in patient monitoring.

The increasing prevalence of spinal muscular atrophy (SMA) is expected to drive growth in the spinraza market. SMA is a rare genetic condition that causes the progressive loss of motor neurons in the spinal cord and brainstem, leading to muscle weakness and atrophy. The rise in SMA cases is largely due to improvements in diagnostic technologies and greater awareness among healthcare professionals and the public. Spinraza is administered via spinal injection to elevate SMN protein levels, directly addressing the genetic cause of SMA. This treatment helps improve motor function and delays the disease's progression. For example, the National Library of Medicine reported in July 2023 that SMA affects roughly 1 in 10,000 to 20,000 newborns, with over 95% of cases stemming from a homozygous deletion of the SMN1 gene. Thus, the increasing prevalence of SMA will contribute significantly to the growth of the spinraza market.

The rise in the number of rare diseases is also expected to drive the growth of the spinraza market. Rare diseases, which affect fewer than 200,000 people, are often severe, chronic, and challenging to diagnose or treat. The increasing recognition of these diseases can be attributed to advances in diagnostic technologies, improved awareness among healthcare providers, and progress in genetic research, making it easier to identify these conditions. Spinraza, which treats the rare genetic disorder SMA, illustrates the potential for similar treatments to address other rare diseases. According to the Food and Drug Administration (FDA) in February 2023, approximately 25 to 30 million Americans are affected by a rare disease, representing about 1 in 10 people. In 2022, more than half of the novel drug approvals - 20 out of 37 - were for rare diseases. Therefore, the rising incidence of rare diseases is driving the growth of the spinraza market.

The growth of the spinraza market is also expected to be supported by the increase in healthcare expenditure. Healthcare spending, which includes costs for medical treatments, medications, and hospital care, is rising due to factors such as an aging population, growing healthcare demands, advancements in medical technology, and increasing prices for services and medications. Higher healthcare expenditure facilitates access to Spinraza by supporting its procurement, distribution, and administration for treating SMA. For instance, the Office for National Statistics reported in May 2024 that total healthcare expenditure in the UK grew by 5.6% in nominal terms from 2022 to 2023, a notable increase compared to the 0.9% growth observed in 2022. As a result, the rise in healthcare spending will continue to drive the growth of the spinraza market.

The key company operating in the spinraza market is Biogen Inc.

North America was the largest region in the spinraza market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in spinraza report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the spinraza market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Spinraza is a drug designed to treat spinal muscular atrophy (SMA) by increasing the production of a key protein that supports motor neuron health, thereby improving muscle strength and function. It works by enhancing the production of the survival motor neuron (SMN) protein through modification of the SMN2 gene, addressing the root cause of SMA.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary clinical indications for spinraza are infantile-onset spinal muscular atrophy, later-onset spinal muscular atrophy, and adult spinal muscular atrophy. Infantile-onset SMA is a genetic disorder that affects infants, leading to muscle weakness and atrophy due to the loss of motor neurons. Symptoms typically appear before six months of age, causing difficulty with movements such as sitting, crawling, and swallowing. Spinraza is used across a range of age groups, including pediatric and adult patients, and is distributed through channels such as retail pharmacies, hospitals or clinics, and online pharmacies.

The spinraza market consists of sales of spinraza (nusinersen), syringes, and vials. Values in this market represent 'factory gate' sales, indicating revenues generated directly by manufacturers or creators of goods and services. These values exclude revenue from resale along the supply chain.

The market value is defined as the revenue generated from sales within the specified geography, measured in USD unless stated otherwise. Consumption values represent revenues earned by organizations in a specific geography, regardless of production location, excluding resale revenues along the supply chain.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.